Quince Therapeutics Inc (QNCX)
$0.8
+0.01
(+0.63%)▲
Live
Performance
- $0.76$0.81$0.80
4.68%
Downside
Day's Volatility :6.14%
Upside
1.54%
- $0.51$1.43$0.80
36.05%
Downside
52 Weeks Volatility :64.23%
Upside
44.06%
Returns
| Period | Quince Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 5.3% | 0.0% |
6 Months | -25.0% | 0.0% |
1 Year | -20.5% | 0.0% |
3 Years | -98.63% | -23.0% |
Highlights
Market Capitalization | 34.3M |
Book Value | $1.09 |
Earnings Per Share (EPS) | -1.26 |
Wall Street Target Price | 3.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -16.5% |
Return On Equity TTM | -79.38% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -29.1M |
Diluted Eps TTM | -1.26 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 275.0%
Technicals Summary
Sell
Neutral
Buy
Quince Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Quince Therapeutics Inc | -0.08% | -25.0% | -20.5% | -98.63% | -96.27% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Quince Therapeutics Inc | NA | NA | NA | 0.0 | -0.79 | -0.16 | NA | 1.09 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Quince Therapeutics Inc | Sell | $34.3M | -96.27% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Quince Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 102.5%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 143.4%
Institutional Holdings
TANG CAPITAL MANAGEMENT LLC
3.47%Vanguard Group Inc
2.81%EPIQ Capital Group, LLC
1.97%Renaissance Technologies Corp
1.12%BlackRock Inc
0.82%HighTower Advisors, LLC
0.79%
Company Information
cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards human clinical testing.
Organization | Quince Therapeutics Inc |
Employees | 32 |
CEO | Dr. Dirk Thye M.D. |
Industry | Healthcare |
